Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis, a two years trial

  • Cabrera-López, Cristina
  • Martí, Teresa
  • Català, Violeta
  • Torres, Ferran|||0000-0002-7355-7913
  • Mateu, Silvia
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
Tuberous sclerosis (TS) is a rare autosomal dominant systemic disease with an estimated prevalence of 1/6000. Renal angiomyolipoma (AML) is a benign tumour with high morbidity frequently present in TS. The aim of the study was to test the effect of rapamycin in reducing the volume of AML in TS. Twenty four-month prospective open-label, single arm, unicentre Phases II andIII study. The primary endpoint was to evaluate the effect of treatment on the reduction of at least 50% AML volume from baseline at 24 months. The secondary endpoints were: average tumour reduction, surgical complications, skin lesions and drug safety. The study population comprised 17 patients, aged.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)

  • Sans-Atxer, Laia
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Fernandez-Llama, Patricia|||0000-0002-7472-2124
Cardiovascular (CV) complications are the major cause of death in autosomal-dominant polycystic kidney disease (ADPKD) patients. Hypertension is common in these patients even before the onset of renal insufficiency. Blood pressure (BP) elevation is a key factor in patient outcome, mainly owing to the high prevalence of target organ damage together with a poor renal prognosis when BP is increased. Many factors have been implicated in the pathogenesis of hypertension, including the renin-angiotensin-aldosterone system (RAAS) stimulation. Polycystin deficiency may also contribute to hypertension because of its potential role in regulating the vascular tone. Early diagnosis and treatment of hypertension improve the CV and renal complications of this population. Ambulatory BP monitoring is recommended for prompt diagnosis of hypertension. CV risk assessment is mandatory. Even though a nonpharmacological approach should not be neglected, RAAS inhibitors are the cornerstone of hypertension treatment. Calcium channel blockers (CCBs) should be avoided unless resistant hypertension is present. The BP should be <140/90 mmHg in all ADPKD patients and a more intensive control (<135/85 mmHg) should be pursued as soon as microalbuminuria or left ventricle hypertrophy is present.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing

  • Trujillano, Daniel
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Ossowski, Stephan|||0000-0002-7416-9568
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Estivill, Xavier|||0000-0002-0723-2256
  • Ars, Elisabet|||0000-0002-4118-4358
Molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) relies on mutation screening of PKD1 and PKD2, which is complicated by extensive allelic heterogeneity and the presence of six highly homologous sequences of PKD1. To date, specific sequencing of PKD1 requires laborious long-range amplifications. The high cost and long turnaround time of PKD1 and PKD2 mutation analysis using conventional techniques limits its widespread application in clinical settings. We performed targeted next-generation sequencing (NGS) of PKD1 and PKD2. Pooled barcoded DNA patient libraries were enriched by in-solution hybridization with PKD1 and PKD2 capture probes. Bioinformatics analysis was performed using an in-house developed pipeline. We validated the assay in a cohort of 36 patients with previously known PKD1 and PKD2 mutations and five control individuals. Then, we used the same assay and bioinformatics analysis in a discovery cohort of 12 uncharacterized patients. We detected 35 out of 36 known definitely, highly likely, and likely pathogenic mutations in the validation cohort, including two large deletions. In the discovery cohort, we detected 11 different pathogenic mutations in 10 out of 12 patients. This study demonstrates that laborious long-range PCRs of the repeated PKD1 region can be avoided by in-solution enrichment of PKD1 and PKD2 and NGS. This strategy significantly reduces the cost and time for simultaneous PKD1 and PKD2 sequence analysis, facilitating routine genetic diagnostics of ADPKD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeted next-generation sequencing in steroid-resistant nephrotic syndrome, mutations in multiple glomerular genes may influence disease severity

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Trujillano, Daniel
  • Santín, Sheila
  • Ossowski, Stephan|||0000-0002-7416-9568
  • Mendizábal, Santiago
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Madrid, Alvaro
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Estivill, Xavier|||0000-0002-0723-2256
  • Ars, Elisabet|||0000-0002-4118-4358
Genetic diagnosis of steroid-resistant nephrotic syndrome (SRNS) using Sanger sequencing is complicated by the high genetic heterogeneity and phenotypic variability of this disease. We aimed to improve the genetic diagnosis of SRNS by simultaneously sequencing 26 glomerular genes using massive parallel sequencing and to study whether mutations in multiple genes increase disease severity. High-throughput mutation analysis was performed in 50 SRNS and/or focal segmental glomerulosclerosis (FSGS) patients, a validation cohort of 25 patients with known pathogenic mutations, and a discovery cohort of 25 uncharacterized patients with probable genetic etiology. In the validation cohort, we identified the 42 previously known pathogenic mutations across NPHS1, NPHS2, WT1, TRPC6, and INF2 genes. In the discovery cohort, disease-causing mutations in SRNS/FSGS genes were found in nine patients. We detected three patients with mutations in an SRNS/FSGS gene and COL4A3. Two of them were familial cases and presented a more severe phenotype than family members with mutation in only one gene. In conclusion, our results show that massive parallel sequencing is feasible and robust for genetic diagnosis of SRNS/FSGS. Our results indicate that patients carrying mutations in an SRNS/FSGS gene and also in COL4A3 gene have increased disease severity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic Variants Associated with Chronic Kidney Disease in a Spanish Population

  • Corredor Mancilla, Zuray Fernanda|||0000-0003-1099-8583
  • Filho, Miguel Inácio da Silva
  • Rodriguez Ribera, Lara
  • Velázquez Henar, Antonia|||0000-0003-3254-4312
  • Hernández, Alba|||0000-0001-6938-1233
  • Catalano, Calogerina
  • Hemminki, Kari|||0000-0002-2769-3316
  • Coll, Elisabet|||0000-0003-0371-6250
  • Silva, Irene|||0000-0002-2723-1031
  • Díaz Gómez, Juan Manuel|||0000-0002-5653-6619
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Vallés Prats, Martí
  • Calabia, Jordi|||0000-0001-6806-9539
  • Försti, Asta|||0000-0002-9857-4728
  • Marcos, Ricard|||0000-0001-7891-357X
  • Pastor Benito, Susana|||0000-0003-2454-5163
Chronic kidney disease (CKD) patients have many affected physiological pathways. Variations in the genes regulating these pathways might affect the incidence and predisposition to this disease. A total of 722 Spanish adults, including 548 patients and 174 controls, were genotyped to better understand the effects of genetic risk loci on the susceptibility to CKD. We analyzed 38 single nucleotide polymorphisms (SNPs) in candidate genes associated with the inflammatory response (interleukins IL-1A, IL-4, IL-6, IL-10, TNF-α, ICAM-1), fibrogenesis (TGFB1), homocysteine synthesis (MTHFR), DNA repair (OGG1, MUTYH, XRCC1, ERCC2, ERCC4), renin-angiotensin-aldosterone system (CYP11B2, AGT), phase-II metabolism (GSTP1, GSTO1, GSTO2), antioxidant capacity (SOD1, SOD2, CAT, GPX1, GPX3, GPX4), and some other genes previously reported to be associated with CKD (GLO1, SLC7A9, SHROOM3, UMOD, VEGFA, MGP, KL). The results showed associations of GPX1, GSTO1, GSTO2, UMOD, and MGP with CKD. Additionally, associations with CKD related pathologies, such as hypertension (GPX4, CYP11B2, ERCC4), cardiovascular disease, diabetes and cancer predisposition (ERCC2) were also observed. Different genes showed association with biochemical parameters characteristic for CKD, such as creatinine (GPX1, GSTO1, GSTO2, KL, MGP), glomerular filtration rate (GPX1, GSTO1, KL, ICAM-1, MGP), hemoglobin (ERCC2, SHROOM3), resistance index erythropoietin (SOD2, VEGFA, MTHFR, KL), albumin (SOD1, GSTO2, ERCC2, SOD2), phosphorus (IL-4, ERCC4 SOD1, GPX4, GPX1), parathyroid hormone (IL-1A, IL-6, SHROOM3, UMOD, ICAM-1), C-reactive protein (SOD2, TGFB1, GSTP1, XRCC1), and ferritin (SOD2, GSTP1, SLC7A9, GPX4). To our knowledge, this is the second comprehensive study carried out in Spanish patients linking genetic polymorphisms and CKD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute pancreatitis promotes the generation of two different exosome populations

  • Jiménez-Alesanco, A.
  • Marcuello, M.
  • Pastor-Jiménez, M.
  • López-Puerto, L.
  • Bonjoch, Laia|||0000-0002-3351-0037
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • de-Madaria, Enrique|||0000-0002-2412-9541
  • Closa Autet, Daniel|||0000-0003-3797-3095
Exosomes are small extracellular vesicles that act as intercellular messengers. Previous studies revealed that, during acute pancreatitis, circulating exosomes could reach the alveolar compartment and activate macrophages. However, proteomic analysis suggested that the most likely origin of these exosomes could be the liver instead of the pancreas. The present study aimed to characterize the exosomes released by pancreas to pancreatitis-associated ascitic fluid (PAAF) as well as those circulating in plasma in an experimental model of taurocholate-induced acute pancreatitis in rats. We provide evidence that during acute pancreatitis two different populations of exosomes are generated with relevant differences in cell distribution, protein and microRNA content as well as different implications in their physiological effects. During pancreatitis plasma exosomes, but not PAAF exosomes, are enriched in the inflammatory miR-155 and show low levels of miR-21 and miR-122. Mass spectrometry-based proteomic analysis showed that PAAF exosomes contains 10-30 fold higher loading of histones and ribosomal proteins compared to plasma exosomes. Finally, plasma exosomes have higher pro-inflammatory activity on macrophages than PAAF exosomes. These results confirm the generation of two different populations of exosomes during acute pancreatitis. Deep understanding of their specific functions will be necessary to use them as therapeutic targets at different stages of the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy

  • Guillén Gómez, Elena|||0000-0002-8498-2579
  • Bardají de Quixano, Beatriz|||0000-0001-7456-355X
  • Ferrer, Sílvia
  • Brotons, Carlos|||0000-0001-9388-6581
  • Knepper, Mark A.
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • Mas, José M.
  • Calero, Francesca|||0000-0002-5758-0769
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Fernandez-Llama, Patricia|||0000-0002-7472-2124
Urinary proteome was analyzed and quantified by tandem mass tag (TMT) labeling followed by bioinformatics analysis to study diabetic nephropathy (DN) pathophysiology and to identify biomarkers of a clinical outcome. We included type 2 diabetic normotensive non-obese males with (n = 9) and without (n = 11) incipient DN (microalbuminuria). Sample collection included blood and urine at baseline (control and DN basal) and, in DN patients, after 3 months of losartan treatment (DN treated). Urinary proteome analysis identified 166 differentially abundant proteins between controls and DN patients, 27 comparing DN-treated and DN-basal patients, and 182 between DN-treated patients and controls. The mathematical modeling analysis predicted 80 key proteins involved in DN pathophysiology and 15 in losartan effect, a total of 95 proteins. Out of these 95, 7 are involved in both processes. VCAM-1 and neprilysin stand out of these 7 for being differentially expressed in the urinary proteome. We observed an increase of VCAM-1 urine levels in DN-basal patients compared to diabetic controls and an increase of urinary neprilysin in DN-treated patients with persistent albuminuria; the latter was confirmed by ELISA. Our results point to neprilysin and VCAM-1 as potential candidates in DN pathology and treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Approach to Vascular Calcification in Patients With Non-dialysis Dependent Chronic Kidney Disease, Mineral-Bone Disorder-Related Aspects

  • Bover, Jordi|||0000-0003-3577-2273
  • Aguilar, Armando
  • Arana Aliaga, Carolt|||0000-0003-1100-5758
  • Molina, Pablo
  • Lloret, Maria Jesus|||0000-0002-1632-7062
  • Ochoa, Jackson
  • Berná, Gerson
  • Gutiérrez-Maza, Yessica G.
  • Rodrigues, Natacha
  • D'Marco, Luis|||0000-0003-0148-891X
  • Górriz, Jose Luis|||0000-0002-1134-9051
Chronic kidney disease (CKD) is associated with a very high morbimortality, mainly from cardiovascular origin, and CKD is currently considered in the high- or very high risk- cardiovascular risk category. CKD-mineral and bone disorders (CKD-MBDs), including vascular and/or valvular calcifications, are also associated with these poor outcomes. Vascular calcification (VC) is very prevalent (both intimal and medial), even in non-dialysis dependent patients, with a greater severity and more rapid progression. Simple X-ray based-scores such as Adragão's (AS) are useful prognostic tools and AS (even AS based on hand-X-ray only) may be superior to the classic Kauppila's score when evaluating non-dialysis CKD patients. Thus, in this mini-review, we briefly review CKD-MBD-related aspects of VC and its complex pathophysiology including the vast array of contributors and inhibitors. Furthermore, although VC is a surrogate marker and is not yet considered a treatment target, we consider that the presence of VC may be relevant in guiding therapeutic interventions, unless all patients are treated with the mindset of reducing the incidence or progression of VC with the currently available armamentarium. Avoiding phosphate loading, restricting calcium-based phosphate binders and high doses of vitamin D, and avoiding normalizing (within the normal limits for the assay) parathyroid hormone levels seem logical approaches. The availability of new drugs and future studies, including patients in early stages of CKD, may lead to significant improvements not only in patient risk stratification but also in attenuating the accelerated progression of VC in CKD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Calcificaciones cardiovasculares en la enfermedad renal crónica: potenciales implicaciones terapéuticas

  • Bover, Jordi|||0000-0003-3577-2273
  • Ureña-Torres, Pablo|||0000-0001-6757-1906
  • Górriz, J.L.
  • Lloret, Maria Jesus|||0000-0002-1632-7062
  • da Silva, I.|||0000-0001-5502-071X
  • Ruiz-García, C.
  • Chang, P.
  • Rodríguez, M.
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
Cardiovascular (CV) calcification is a highly prevalent condition at all stages of chronic kidney disease (CKD) and is directly associated with increased CV and global morbidity and mortality. In the first part of this review, we have shown that CV calcifications represent an important part of the CKD-MBD complex and are a superior predictor of clinical outcomes in our patients. However, it is also necessary to demonstrate that CV calcification is a modifiable risk factor including the possibility of decreasing (or at least not aggravating) its progression with iatrogenic manoeuvres. Although, strictly speaking, only circumstantial evidence is available, it is known that certain drugs may modify the progression of CV calcifications, even though a direct causal link with improved survival has not been demonstrated. For example, non-calcium-based phosphate binders demonstrated the ability to attenuate the progression of CV calcification compared with the liberal use of calcium-based phosphate binders in several randomised clinical trials. Moreover, although only in experimental conditions, selective activators of the vitamin D receptor seem to have a wider therapeutic margin against CV calcification. Finally, calcimimetics seem to attenuate the progression of CV calcification in dialysis patients. While new therapeutic strategies are being developed (i.e. vitamin K, SNF472, etc.), we suggest that the evaluation of CV calcifications could be a diagnostic tool used by nephrologists to personalise their therapeutic decisions.